M. Lamar

Learn More
BACKGROUND The mesenchymal-epithelial transition factor (MET) receptor is dysregulated in hepatocellular carcinoma (HCC), and tivantinib (ARQ 197) is an oral, selective, MET inhibitor. METHODS This Phase-1b study assessed tivantinib safety as primary objective in patients with previously treated HCC and Child-Pugh A or B liver cirrhosis. Patients received(More)
PURPOSE This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of tivantinib combined with sorafenib in patients with advanced solid tumors. MATERIALS AND METHODS A standard 3 + 3 dose escalation design was used. At the RP2D, expansion cohorts in 5 tumor types could be enrolled.(More)
Fractional anisotropy (FA), a widely used measure of fiber integrity based on diffusion tensor imaging (DTI), is theoretically confounded by several other quantities including the degree of fiber orientation incoherence within each voxel, and partial volume effects from neighboring gray matter or CSF. High angular resolution diffusion imaging (HARDI) can(More)
  • 1